Journal Article

Treatment Patterns, Resource Use, and Economic Outcomes Associated With Atypical Antipsychotic Prescriptions in Children and Adolescents With Attention-Deficit Hyperactivity Disorder in Quebec/Modèles de traitement, utilisation des ressources, et résultats économiques associés aux prescriptions d'antipsychotiques atypiques aux enfants et adolescents souffrant du trouble de déficit d'attention avec hyperactivité au Québec

Hodgkins, Paul, De, Gourab, Lachaine, Jean, Heroux, Julie, Amor, Leila Ben, van Stralen, Judy, Yang, Hongbo, Sikirica, Vanja

2014

Overview

To assess treatment patterns, health care resource utilization (HRU), and costs among previously stimulant-treated children and adolescents with attention-deficit hyperactivity disorder (ADHD) receiving atypical antipsychotic (AAP) prescriptions in Quebec. Health care claims data extracted from Quebec's provincial health plan database between March 2007 and February 2012 were analyzed. Children and adolescents (6 to 17 years) with ADHD who were taking a stimulant and either switched to, or augmented with, an AAP (with the first AAP defined as the index AAP) without a documented diagnosis for which AAPs are Health Canada-approved were included. Discontinuation, augmentation, and switching of the index AAP during the 12-month, follow-up period were estimated using Kaplan-Meier survival analysis. HRU and costs for the 6 months before (baseline period) and after initiation of the index AAP were compared. A total of 453 children and adolescents with ADHD, mostly male (74.6%) and aged 6 to 12 years (73.7%), met the inclusion criteria. The 12-month discontinuation, augmentation, and switching rates were 45.5%, 68.2%, and 80.7%, respectively. Patients had, on average, more all-cause prescription fills (22.2, compared with 13.3) and incurred more all-cause pharmacy ($889, compared with $710), total medical ($1096, compared with $644), and total health care ($1985, compared with $1354) costs during the 6-month study period than during the 6-month baseline period (all P < 0.05). Similarly, ADHD-related total health care costs were higher during the study period ($1269, compared with $835; P < 0.05); all-cause and ADHD-related total health care costs increased by 46.6% and 52.0%, respectively. Use of an AAP among stimulant-treated children and adolescents with ADHD in Quebec was associated with high rates of therapy changes and increased HRU and costs.

• Publisher: SAGE PUBLICATIONS, INC
• Subject: Attention deficit hyperactivity disorder / Children & youth / Drug therapy / Prescription drugs / Psychiatry / Teenagers